Will establish small molecule and biologics active drug substance manufacturing in the region
AbbVie is to invest US$320m to establish small molecule and biologics active drug substance manufacturing in Singapore. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie's oncology and immunology pipeline to serve global markets.
The investment is expected to result in the addition of more than 250 new employees. AbbVie anticipates that the new facility will be fully operational by 2019.
The facility will be AbbVie's first manufacturing presence in Asia, but the firm already has research and development (R&D) functions in Tokyo, Japan and Shanghai, China, as well as commercial operations throughout the region. AbbVie's existing presence in Singapore includes 120 staff, supporting commercial operations, global R&D and general operations.
'As Asia's fastest-growing bio-cluster, Singapore is an ideal location to expand our manufacturing network while maintaining rigorous standards of quality and delivery for the patients we serve around the world,' said Azita Saleki-Gerhardt, Senior Vice President, Operations, AbbVie.
'Our presence in Singapore will help assure geographic balance and continuity of product supply as well as increased capacity to deliver on our growing biologics and small molecule product pipeline.'
AbbVie is focused on delivering its small molecule and biologics pipeline to address significant unmet medical needs and advance the well-being of patients across the immunology, liver disease, oncology, neuroscience and kidney disease therapeutic areas.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott.